The company said it announced in Q1 of fiscal 2024 a change in operating segments that moves its cell analysis business from life sciences and applied markets to diagnostics and genomics.

8-KOther EventsFiled Sep 3, 2024Period of report Sep 3, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said it announced in Q1 of fiscal 2024 a change in operating segments that moves its cell analysis business from life sciences and applied markets to diagnostics and genomics.
Agilent said it continues to have three business segments, namely life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab, and that it has recast historical segment financial information to the new presentation.
The company said it recast, in Exhibit 99.1, Item 1, Item 2, Item 7 and Item 8 of its Form 10-K for the year ended October 31, 2023 to reflect the new segment structure.
The company said this filing does not reflect information or events after its Form 10-K was filed, other than segment information adjustments, and that more recent information is in its Form 10-Q for the quarter ended July 31, 2024.

Summary

AI-written

Analysis scope · Filing body only (exhibits excluded)We analyzed the filing body only. The exhibits exceeded the length limit and were excluded, so figures, financial statements and presentation materials in them were not reviewed.

Moving cell analysis business between segments

The company said it announced in Q1 of fiscal 2024 a change in operating segments that moves its cell analysis business from life sciences and applied markets to diagnostics and genomics.

Source · Based on the filing body (exhibits excluded)

Three segments retained and prior information recast

Agilent said it continues to have three business segments, namely life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab, and that it has recast historical segment financial information to the new presentation.

Source · Based on the filing body (exhibits excluded)

Recast items in Exhibit 99.1

The company said it recast, in Exhibit 99.1, Item 1, Item 2, Item 7 and Item 8 of its Form 10-K for the year ended October 31, 2023 to reflect the new segment structure.

Source · Based on the filing body (exhibits excluded)

Scope of recast and where to find latest information

The company said this filing does not reflect information or events after its Form 10-K was filed, other than segment information adjustments, and that more recent information is in its Form 10-Q for the quarter ended July 31, 2024.

Source · Based on the filing body (exhibits excluded)

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.